Does vevye treat dry eyes?

Does Vevye treat dry eyes?

Vevye is a prescription eye drop approved for treating the signs and symptoms of dry eye disease. It contains cyclosporine 0.1%, which works by inhibiting calcineurin and reducing inflammation on the eye's surface. The medication is preservative-free and preservative-free formulations help patients with sensitive eyes.

What happens if you stop using Vevye?

Patients may see symptoms return once they discontinue Vevye. The drug does not cure dry eye disease. It manages the inflammation responsible for producing symptoms such as burning, grittiness, and reduced tear production. Patients who stop the twice-daily dosing often experience a relapse of symptoms.

Why are companies challenging this patent?

Patent disputes surround the 0.1% cyclosporine formulation. Companies have filed challenges seeking early entry into the market before the listed patents expire. Challenges typically focus on obviousness and novelty of the formulation. The company owning Vevye has already responded to some challenges through litigation.

When does the patent expire?

The main patent covering Vevye's formulation expires in 2034. Additional patents and regulatory exclusivities may push full generic entry later. Companies looking for biosimilar-like opportunities for eye drops expect to enter after 2034.